{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:47:39Z","timestamp":1767134859221,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":63,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd004678","type":"reference-entry","created":{"date-parts":[[2004,1,29]],"date-time":"2004-01-29T13:02:36Z","timestamp":1075381356000},"source":"Crossref","is-referenced-by-count":21,"title":["Therapy with glatiramer acetate for multiple sclerosis"],"prefix":"10.1002","author":[{"given":"Luca M.","family":"Munari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lovati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexei","family":"Boiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,20]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD004678-BIB1|cit1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM198708133170703","article-title":"A pilot trial of Cop 1 in exacerbationg-remitting multiple sclerosis","volume":"317","author":"Bornstein","year":"1987","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB2|cit2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1212\/WNL.41.4.533","article-title":"A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis","volume":"41","author":"Bornstein","year":"1991","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678-BIB4|cit3","series-title":"Journal of Neurosurgery","first-page":"187","article-title":"The extension phase of the European-Canadian MRI study demonstrates a sustained effect of glatiramer acetate in relapsing-remitting multiple sclerosis","author":"Comi","year":"2001"},{"issue":"3","key":"10.1002\/14651858.CD004678-BIB5|cit4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","article-title":"European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of Glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing-remitting multiple sclerosis","volume":"149","author":"Comi","year":"2001","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD004678-BIB3|cit5","first-page":"A289","article-title":"The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment","volume":"52 Suppl 2","author":"Comi","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB6|cit6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1212\/WNL.57.4.731","article-title":"Glatiramer acetate reduces the proportion of new MS lesions evolving into \"black holes\"","volume":"57","author":"Filippi","year":"2001","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004678-BIB7|cit7","first-page":"187","article-title":"The effect of glatiramer acetate on brain volume changes in patients with relapsing-remitting multiple sclerosis","volume":"94","author":"Rovaris","year":"2001","journal-title":"Journal of Neurosurgery"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB8|cit8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/WNL.54.4.813","article-title":"Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment","volume":"54","author":"Ge","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB9|cit9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1212\/WNL.52.4.894-c","article-title":"Extended use of glatiramer acetate (Copaxone) for MS [Letter]","volume":"52","author":"Greenstein","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678-BIB14|cit10","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/ana.410360727","article-title":"Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1","volume":"36 Suppl","author":"Johnson","year":"1994","journal-title":"Annals Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004678-BIB15|cit11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/135245859600100606","article-title":"Management of relapsing\/remitting multiple sclerosis with copolymer 1 (Copaxone)","volume":"1","author":"Johnson","year":"1996","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678-BIB16|cit12","first-page":"973","article-title":"The U.S.Phase III Copolymer 1 Study Group. Antibodies to Copolymer 1 do not interfere with the clinical effect [Abstract]","volume":"38","author":"Johnson","year":"1995","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD004678-BIB10|cit13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double.-blind, placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004678-BIB11|cit14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.50.3.701","article-title":"Extended use of glatiramer acetate (copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group","volume":"50","author":"Johnson","year":"1998","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB12|cit15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/135245850000600407","article-title":"Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group","volume":"6","author":"Johnson","year":"2000","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678-BIB13|cit16","first-page":"S38","article-title":"Effects of copolymer on neurologic disability in patients with relapsing-remitting multiple sclerosis: results of a phase III trial [Abstract]","volume":"242","author":"Johnson","year":"1995","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004678-BIB17|cit17","first-page":"103","article-title":"Copolymer-1 reduces the relapse rate and positively influences disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center double-blind, placebo- controlled trial [Abstract]","volume":"2","author":"Schiffer","year":"1995","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004678-BIB18|cit18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0022-510X(77)90220-9","article-title":"Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report","volume":"31","author":"Abramsky","year":"1977","journal-title":"Journal of Neurolological Sciences"},{"issue":"7 Suppl 2","key":"10.1002\/14651858.CD004678-BIB19|cit19","first-page":"69","article-title":"Copolymer 1 as therapy for multiple sclerosis: the cons","volume":"38","author":"Baumhefner","year":"1988","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004678-BIB20|cit20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.410110314","article-title":"Multiple sclerosis: trial of a synthetic polypeptide","volume":"11","author":"Bornstein","year":"1982","journal-title":"Annals of Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD004678-BIB21|cit21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0165-5728(01)00250-8","article-title":"Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone","volume":"115","author":"Brenner","year":"2001","journal-title":"Journal of Neuroimmunology"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB22|cit22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/135245850100700401","article-title":"Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS","volume":"7","author":"Chen","year":"2001","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004678-BIB23|cit23","first-page":"A470","article-title":"Assessment of the efficacy of Copolymer-1 in the Treatment of Multiple Sclerosis by Quantitative MRI","volume":"45","author":"Cohen","year":"1995","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004678-BIB24|cit24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/135245850000600603","article-title":"Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis","volume":"6","author":"Constantinescu","year":"2000","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD004678-BIB25|cit25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/1531-8249(200005)47:5<686::AID-ANA29>3.0.CO;2-G","article-title":"Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial","volume":"47","author":"Seze","year":"2000","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD004678-BIB26|cit26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1172\/JCI8970","article-title":"Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis","volume":"105","author":"Duda","year":"2000","journal-title":"Journal of Clinical Investigation"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB27|cit27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/brain\/124.4.705","article-title":"Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells","volume":"124","author":"Farina","year":"2001","journal-title":"Brain"},{"issue":"1","key":"10.1002\/14651858.CD004678-BIB28|cit28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00002826-200201000-00002","article-title":"Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration","volume":"25","author":"Flechter","year":"2002","journal-title":"Clinical Neuropharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD004678-BIB29|cit29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-510X(02)00047-3","article-title":"Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up","volume":"197","author":"Flechter","year":"2002","journal-title":"Journal of Neurological Sciences"},{"issue":"11","key":"10.1002\/14651858.CD004678-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.57.11.1976","article-title":"HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis","volume":"57","author":"Fusco","year":"2001","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004678-BIB31|cit31","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1172\/JCI200214380","article-title":"Glatiramer acetate (Copaxone) therapy induces CD8+ T cella response in patients with multiple sclerosis","volume":"109","author":"Karandikar","year":"2002","journal-title":"Journal of Clinical Investigation"},{"issue":"6","key":"10.1002\/14651858.CD004678-BIB32|cit32","first-page":"349","article-title":"A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy","volume":"7","author":"Khan","year":"2001","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678-BIB33|cit33","first-page":"S23","article-title":"Optic Neuritis in Multiple Sclerosis Patients Treated with Copaxone","volume":"244","author":"Kott","year":"1997","journal-title":"Journal of Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD004678-BIB34|cit34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0022-510X(00)00401-9","article-title":"Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability\/time curves. The Copolymer 1 Multiple Sclerosis Study Group","volume":"181","author":"Liu","year":"2000","journal-title":"Journal of Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.50.4.1127","article-title":"Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis","volume":"50","author":"Mancardi","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678-BIB36|cit36","first-page":"213","article-title":"Copolymer 1 in relapsing-remitting multiple sclerosis: a multi-centre trial","volume-title":"Frontiers in Multiple Sclerosis: Clinical Research and Therapy","author":"Meiner","year":"1997"},{"issue":"1-2","key":"10.1002\/14651858.CD004678-BIB37|cit37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-5728(98)00191-X","article-title":"Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2\/Th3 immune-deviation","volume":"92","author":"Miller","year":"1998","journal-title":"Journal of Neuroimmunology"},{"issue":"1-2","key":"10.1002\/14651858.CD004678-BIB38|cit38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-5728(00)00263-0","article-title":"Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients","volume":"108","author":"Qin","year":"2000","journal-title":"Journal of Neuroimmunology"},{"issue":"3","key":"10.1002\/14651858.CD004678-BIB39|cit39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1212\/WNL.58.3.417","article-title":"MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients","volume":"58","author":"Sormani","year":"2002","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004678-BIB40|cit40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archneur.56.3.319","article-title":"Neuropsychologic status in multiple sclerosis after treatment with glatiramer","volume":"56","author":"Weinstein","year":"1999","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004678-BIB41|cit41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/135245850100700107","article-title":"MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center","volume":"7","author":"Wolinsky","year":"2001","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678-BIB42|cit42","unstructured":"Markowitz C A multinational, multicenter, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of glatiramer acetate for injection in primary progressive multiple sclerosis patients http:\/\/www.uphs.upenn.edu\/neuro\/clintrial\/MS-Promise-Markowitz.htm 2000"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004678-BIB43|cit43","first-page":"S65","article-title":"The PROMiSe trial: baseline data review and progress report","volume":"10","author":"Wolinsky","year":"2004","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678-BIB44|cit44","unstructured":"Markowitz C A multinational, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of 2 doses of glatiramer acetate orally administered in relapsing remitting multiple sclerosis patients http:\/\/www.uphs.upenn.edu\/neuro\/clintrial\/MS-Coral-Markowitz.htm"},{"key":"10.1002\/14651858.CD004678-BIB45|cit45","unstructured":"Teva Pharmaceutical Industries Ltd Teva reports results from oral copaxone study http:\/\/www.copaxone.com"},{"key":"10.1002\/14651858.CD004678-BIB46|cit46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1191\/1352458503ms932oa","article-title":"Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials","volume":"9","author":"Martinelli Boneschi","year":"2003","journal-title":"Multiple Sclerosis"},{"issue":"6563","key":"10.1002\/14651858.CD004678-BIB47|cit47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/379343a0","article-title":"Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein","volume":"379","author":"Brocke","year":"1996","journal-title":"Nature"},{"issue":"2","key":"10.1002\/14651858.CD004678-BIB48|cit48","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S1474-4422(05)00974-9","article-title":"Evidence for use of glatiramer acetate in multiple sclerosis","volume":"4","author":"Caramanos","year":"2005","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1002\/14651858.CD004678-BIB49|cit49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(05)00975-0","article-title":"Evidence for use of glatiramer acetate in multiple sclerosis","volume":"4","author":"Comi","year":"2005","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1002\/14651858.CD004678-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archderm.135.10.1277","article-title":"Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis (letter)","volume":"135","author":"Drago","year":"1999","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1002\/14651858.CD004678-BIB51|cit51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1017\/S0317167100002845","article-title":"Lipoatrophy in patients with multiple sclerosis on glatiramer acetate","volume":"31","author":"Edgar","year":"2004","journal-title":"Can J Neurol Sci."},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB52|cit52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/WNL.54.4.813","article-title":"Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment","volume":"54","author":"Ge","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB53|cit53","first-page":"287","article-title":"Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis","volume":"68","author":"Hwang","year":"2001","journal-title":"Cutis"},{"issue":"1","key":"10.1002\/14651858.CD004678-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of randomised trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled clinical trials"},{"issue":"11","key":"10.1002\/14651858.CD004678-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004678-BIB56|cit56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s004150050568","article-title":"Localized lipoatrophy after prolonged treatment with copolymer 1","volume":"247","author":"Mancardi","year":"2000","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004678-BIB57|cit57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1474-4422(05)00976-2","article-title":"Evidence for use of glatiramer acetate in multiple sclerosis (Authors' reply)","volume":"4","author":"Munari","year":"2005","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1002\/14651858.CD004678-BIB58|cit58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678-BIB59|cit59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"issue":"1","key":"10.1002\/14651858.CD004678-BIB60|cit60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/PL00000576","article-title":"Coplymer 1: from basic research to clinical application","volume":"53","author":"Teitelbaum","year":"1997","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"2","key":"10.1002\/14651858.CD004678-BIB61|cit61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ana.410010207","article-title":"Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis","volume":"1","author":"Wisniewski","year":"1977","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004678-BIB62|cit62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta-blockade during and after myocardial infarction: an overview of the randomised trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"11","key":"10.1002\/14651858.CD004678-BIB63|cit63","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1474-4422(04)00899-3","article-title":"Lack of evidence for use of glatiramer acetate in multiple sclerosis","volume":"3","author":"Munari","year":"2004","journal-title":"Lancet Neurol"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004678.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T00:00:00Z","timestamp":1273622400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004678\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:38:22Z","timestamp":1628530702000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004678"}},"subtitle":[],"editor":[{"given":"Luca M.","family":"Munari","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2003,10,20]]},"references-count":63,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004678","relation":{},"subject":[],"published":{"date-parts":[[2003,10,20]]}}}